DE69736995T2 - Kristallisierbare Zusammensetzungen, die einen Komplex von Protease-Domäne NS3 und NS4A aus dem Hepatitis C Virus enthalten, und damit bereitgestellte Kristalle - Google Patents

Kristallisierbare Zusammensetzungen, die einen Komplex von Protease-Domäne NS3 und NS4A aus dem Hepatitis C Virus enthalten, und damit bereitgestellte Kristalle Download PDF

Info

Publication number
DE69736995T2
DE69736995T2 DE69736995T DE69736995T DE69736995T2 DE 69736995 T2 DE69736995 T2 DE 69736995T2 DE 69736995 T DE69736995 T DE 69736995T DE 69736995 T DE69736995 T DE 69736995T DE 69736995 T2 DE69736995 T2 DE 69736995T2
Authority
DE
Germany
Prior art keywords
amino acids
ile
val
lys
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69736995T
Other languages
German (de)
English (en)
Other versions
DE69736995D1 (de
Inventor
Joseph L. Natick Kim
Kurt A. Derry Morgenstern
Chao Brookline Lin
Ted Maynard Fox
John A. Belmont Thomson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69736995D1 publication Critical patent/DE69736995D1/de
Publication of DE69736995T2 publication Critical patent/DE69736995T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54Organic compounds
    • C30B29/58Macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30Drug targeting using structural data; Docking or binding prediction
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2299/00Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/18Togaviridae; Flaviviridae
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69736995T 1996-09-12 1997-09-12 Kristallisierbare Zusammensetzungen, die einen Komplex von Protease-Domäne NS3 und NS4A aus dem Hepatitis C Virus enthalten, und damit bereitgestellte Kristalle Expired - Lifetime DE69736995T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2527496P 1996-09-12 1996-09-12
US25274P 1996-09-12
US731336 1996-10-18
US08/731,336 US6153579A (en) 1996-09-12 1996-10-18 Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex

Publications (2)

Publication Number Publication Date
DE69736995D1 DE69736995D1 (de) 2007-01-04
DE69736995T2 true DE69736995T2 (de) 2007-09-20

Family

ID=26699520

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69736995T Expired - Lifetime DE69736995T2 (de) 1996-09-12 1997-09-12 Kristallisierbare Zusammensetzungen, die einen Komplex von Protease-Domäne NS3 und NS4A aus dem Hepatitis C Virus enthalten, und damit bereitgestellte Kristalle
DE69723485T Expired - Lifetime DE69723485T2 (de) 1996-09-12 1997-09-12 Verfahren zur Identifizierung von Wirkstoffen gegen HCV durch Verwendung von Strukturkoordinaten der Hepatitis-C-Virus-Protease
DE69712085T Expired - Lifetime DE69712085T2 (de) 1996-09-12 1997-09-12 Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69723485T Expired - Lifetime DE69723485T2 (de) 1996-09-12 1997-09-12 Verfahren zur Identifizierung von Wirkstoffen gegen HCV durch Verwendung von Strukturkoordinaten der Hepatitis-C-Virus-Protease
DE69712085T Expired - Lifetime DE69712085T2 (de) 1996-09-12 1997-09-12 Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle

Country Status (12)

Country Link
US (2) US6153579A (https=)
EP (1) EP0935609B1 (https=)
JP (1) JP2001501602A (https=)
AT (3) ATE244729T1 (https=)
AU (1) AU736857B2 (https=)
CA (1) CA2264964A1 (https=)
DE (3) DE69736995T2 (https=)
DK (1) DK0935609T3 (https=)
ES (2) ES2202228T3 (https=)
IL (1) IL128826A0 (https=)
PT (2) PT1118619E (https=)
WO (1) WO1998011134A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100509388B1 (ko) 1996-10-18 2005-08-23 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 간염 c 바이러스 ns3 프로테아제의 저해제
JP2002534084A (ja) 1999-01-08 2002-10-15 ブリストル−マイヤーズ スクイブ カンパニー C型肝炎ウイルスns3プロテアーゼの修飾形
US6524589B1 (en) * 1999-04-08 2003-02-25 Schering Corporation Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same
AU775928B2 (en) 1999-10-14 2004-08-19 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
US7491808B2 (en) 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
MXPA02012605A (es) 2000-06-28 2003-05-14 Squibb Bristol Myers Co Moduladores selectivos del receptor androgeno y metodo para su identificacion, dise°o y uso.
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
JP2004535758A (ja) 2000-11-14 2004-12-02 ブリストル−マイヤーズ スクイブ カンパニー リンパ様細胞lsi−01から分泌される新規なヒトセルピンをコードするポリヌクレオチド
WO2002088303A2 (en) 2001-04-03 2002-11-07 Bristol-Myers Squibb Company Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof
US20030027315A1 (en) * 2001-09-24 2003-02-06 Ada Yonath Methods of growing crystals of free and antibiotic complexed large ribosomal subunits, and methods of rationally designing or identifying antibiotics using structure coordinate data derived from such crystals
WO2005000308A2 (en) * 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
KR20060120166A (ko) 2003-10-27 2006-11-24 버텍스 파마슈티칼스 인코포레이티드 Hcv ns3-ns4a 단백질분해효소 저항성 돌연변이
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP2392589A3 (en) 2005-11-11 2012-06-20 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP1991229A2 (en) 2006-02-27 2008-11-19 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
EP1993994A2 (en) * 2006-03-16 2008-11-26 Vertex Pharmceuticals Incorporated Deuterated hepatitis c protease inhibitors
US8440443B1 (en) 2006-05-16 2013-05-14 Merck Sharp & Dohme Corp. MEK1 polypeptides
DK2114924T3 (da) 2007-02-27 2012-04-10 Vertex Pharma Co-krystaller og farmaceutiske sammensætninger omfattende disse
JP2010519329A (ja) 2007-02-27 2010-06-03 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ阻害剤
CN101835774B (zh) 2007-08-30 2014-09-17 弗特克斯药品有限公司 共晶体和包含该共晶体的药物组合物
US8988881B2 (en) * 2007-12-18 2015-03-24 Sandia Corporation Heat exchanger device and method for heat removal or transfer
US9005417B1 (en) 2008-10-01 2015-04-14 Sandia Corporation Devices, systems, and methods for microscale isoelectric fractionation
US9795961B1 (en) 2010-07-08 2017-10-24 National Technology & Engineering Solutions Of Sandia, Llc Devices, systems, and methods for detecting nucleic acids using sedimentation
US9261100B2 (en) 2010-08-13 2016-02-16 Sandia Corporation Axial flow heat exchanger devices and methods for heat transfer using axial flow devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
US5353236A (en) * 1992-04-23 1994-10-04 The Board Of Trustees Of The Leland Stanford University High-resolution crystallographic modelling of a macromolecule
US5453937A (en) * 1993-04-28 1995-09-26 Immunex Corporation Method and system for protein modeling
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.

Also Published As

Publication number Publication date
IL128826A0 (en) 2000-01-31
DE69723485T2 (de) 2004-05-27
WO1998011134A1 (en) 1998-03-19
ATE244729T1 (de) 2003-07-15
DE69712085D1 (de) 2002-05-23
ATE216400T1 (de) 2002-05-15
AU4414597A (en) 1998-04-02
CA2264964A1 (en) 1998-03-19
AU736857B2 (en) 2001-08-02
DE69723485D1 (de) 2003-08-14
HK1022700A1 (en) 2000-08-18
JP2001501602A (ja) 2001-02-06
PT1118619E (pt) 2003-11-28
PT935609E (pt) 2002-09-30
EP0935609A1 (en) 1999-08-18
HK1038573A1 (en) 2002-03-22
US6153579A (en) 2000-11-28
ES2175462T3 (es) 2002-11-16
DE69736995D1 (de) 2007-01-04
DE69712085T2 (de) 2002-11-28
ATE346088T1 (de) 2006-12-15
ES2202228T3 (es) 2004-04-01
EP0935609B1 (en) 2002-04-17
US6303287B1 (en) 2001-10-16
DK0935609T3 (da) 2002-07-22

Similar Documents

Publication Publication Date Title
DE69736995T2 (de) Kristallisierbare Zusammensetzungen, die einen Komplex von Protease-Domäne NS3 und NS4A aus dem Hepatitis C Virus enthalten, und damit bereitgestellte Kristalle
Kim et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide
ES2456702T3 (es) Bolsillo de unión del inhibidor de la polimerasa NS5B del virus de la hepatitis C
Yao et al. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease–helicase
Love et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site
Bewley et al. Solution structure of cyanovirin-N, a potent HIV-inactivating protein
De Francesco et al. A zinc binding site in viral serine proteinases
US7894996B2 (en) Structure of the hepatitis C NS5A protein
DE602004011047T2 (de) Kristallstruktur von der humanen coronavirus 229e hauptproteinase und deren verwendung zur entwicklung von sars-inhibitoren
US20020042046A1 (en) Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
CN101851274B (zh) 抑制丙型肝炎病毒侵入的多肽
Liu et al. Hepatitis C NS3 protease inhibition by peptidyl-α-ketoamide inhibitors: kinetic mechanism and structure
US6434489B1 (en) Compositions of hepatitis C virus NS5B polymerase and methods for crystallizing same
Kang et al. Crystallization and preliminary X-ray crystallographic analysis of the helicase domain of hepatitis C virus NS3 protein
EP1364961B1 (en) Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained
EP1118619B1 (en) Method to identify agents active against HCV by using the structure coordinates of hepatitis C virus protease
Yao et al. Application of structural biology tools in the study of viral hepatitis and the design of antiviral therapy
Xu et al. Crystallization and preliminary crystallographic analysis of the heptad-repeat complex of SARS coronavirus spike protein
HK1022700B (en) Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained
HK1059792A (en) Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained
HK1038573B (en) Method to identify agents active against hcv by using the structure coordinates of hepatitis c virus protease
Abdalrazaq et al. INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL SCIENCES
Cuff Crystal structure of a molluscan hemocyanin
Sabet Characterization, cloning and expression of NS3 protein gene of hepatitis C genotype 4A

Legal Events

Date Code Title Description
8364 No opposition during term of opposition